CorMedix: DefenCath and Rezzayo Expand Growth Path, but Reimbursement Cliff Remains

What happened

A Zacks article highlights CorMedix's evolution beyond a single-product launch, with DefenCath driving current revenue and Rezzayo adding long-term potential despite known reimbursement headwinds. The piece reinforces the company's shift to a broader anti-infective platform following the Melinta acquisition. However, the master report underscores that the July 2026 TDAPA step-down remains the dominant risk, with no margin of safety at current prices. Management's FY2026 guidance and the upcoming Analyst Day are critical for validating unit adoption and synergy realization. The news does not alter the fundamental thesis but emphasizes the need for execution on both DefenCath utilization and Rezzayo's clinical catalyst.

Implication

The article reinforces the dual-driver thesis, but investors must remain focused on the July 2026 reimbursement reset. Near-term catalysts include Analyst Day KPI disclosure and Rezzayo Phase 3 data. The stock trades at a low EV/EBITDA multiple but carries significant policy risk. Conviction is moderate given the binary nature of the reimbursement step-down. Position sizing should account for potential downside if utilization fails to offset pricing pressure.

Thesis delta

The news does not change the core investment thesis but adds weight to the Rezzayo catalyst timeline. The shift from a purely DefenCath-centric story to a broader platform narrative was already anticipated. The delta is that the market may start pricing in Rezzayo optionality earlier, but the primary risk remains the TDAPA cliff.